Written and maintained by CASRAI Editorial Board
Last updated
Alzheimer’s Research & Therapy is an open access, peer-reviewed journal for translational Alzheimer’s disease research. It is now hosted on Springer Nature Link, charges an article processing charge (APC) on acceptance, and publishes research articles, reviews, debates, comments and other article types. This profile is for researchers and research administrators deciding whether the journal fits a manuscript. Every fact below comes from the journal’s own pages, read on 2026-11-08, and the fee and metric figures can change, so confirm them on the journal before you budget or submit.
What it is
The journal describes itself as “the major forum for translational research into Alzheimer’s disease.” It is an international, peer-reviewed, open access title. Its aims and scope page lists basic research with a translational focus, clinical trials, research into drug discovery and development, and epidemiologic studies, plus reviews, viewpoints, commentaries, debates and reports. Alzheimer’s disease is the primary focus, but the scope also covers translational research into other neurodegenerative diseases.
A change worth knowing if you are looking for the journal: the older BioMed Central address (alzres.biomedcentral.com) now redirects to the journal’s page on Springer Nature Link (link.springer.com/journal/13195), where the aims and scope, submission guidelines and fees pages are now found.
Who runs it and what it covers
The journal’s home page lists it as affiliated with Alzheimer’s Disease International, with Alzheimer’s Research UK shown as a partner society. Its Editors-in-Chief, as listed on 2026-11-08, are Delphine Boche, Kristian Steen Frederiksen and Charlotte Teunissen. The publisher’s submission guidelines refer to BioMed Central editorial policies, which apply to the journal.
Metrics as displayed by the journal
The journal’s home page shows a 2025 Journal Impact Factor of 8.9, a 5-year Journal Impact Factor of 9.8, a median of 6 days from submission to first decision, and 3.3 million downloads in 2025. The descriptive text on the same page separately states an average time to first decision within 5 weeks. The two timing figures use different definitions (median versus average), so they are not in conflict, but quote them with their definition. For how journals handle peer review in general, see the dictionary entry. These are the journal’s own figures as displayed on 2026-11-08.
How to use the journal’s pages as an author
- Open the journal home page on Springer Nature Link (link.springer.com/journal/13195) and read Aims and scope first, to check that your manuscript is translational and fits one of the listed areas.
- Open Fees and funding to see the current APC and the waiver and discount information.
- Open the Pre-submission checklist and Submission guidelines, then the formatting page for your article type (the guidelines list Research articles, Debates, Comment, Correspondence, Meeting reports, Reviews, Mini review and Matters Arising).
- Prepare the manuscript as a DOC/DOCX, RTF or TeX/LaTeX file, with double line spacing, line and page numbering and SI units.
- Add the required “Availability of data and materials” section. BioMed Central endorses the FORCE11 Data Citation Principles and asks that publicly available datasets be cited with an accession number or DOI.
- Write a cover letter explaining why the manuscript belongs in the journal, any policy issues, competing interests, confirmation that all authors approved the submission and that the work is not published or submitted elsewhere.
- Optionally suggest peer reviewers in the cover letter, using institutional email addresses or an ORCID or Scopus ID so the editor can verify identity. Falsified reviewer details lead to rejection.
- Use the Submit your manuscript link on the journal pages. A manuscript can only be submitted by one of its authors, not by a third party.
Fees, licence and waivers
| Item | What the journal states (checked 2026-11-08) |
|---|---|
| APC | GBP 3,090 / USD 4,390 / EUR 3,490, subject to VAT or local taxes; payable on acceptance and set at the acceptance date |
| Waivers | Waivers or discounts for corresponding authors in the lowest-income countries; other requests are considered case by case and must be made at submission |
| Licence | CC BY-NC-ND 4.0 or CC BY 4.0, with authors retaining copyright (see Creative Commons) |
| Publishing model | Open access |
Because the APC is set when the manuscript is accepted, the figure on the day you submit may differ from the one you pay.
Strengths and limits
- Strength: a clear translational remit. The scope states that clinical trials, drug discovery and development, and epidemiology all sit alongside basic research with a translational focus, so the journal is not limited to one study design.
- Strength: stated review speed. The journal publishes both a median time to first decision and an average, which lets you compare it with other titles on the same definition.
- Limit: a cost to the author. The APC applies on acceptance, and waivers are targeted at lowest-income-country corresponding authors, with other cases handled individually.
- Limit: a defined focus. The primary focus is Alzheimer’s disease; work on other neurodegenerative conditions fits only where it is translational.
- Limit: metrics are the journal’s own. The impact factor and download figures on its home page are not a substitute for checking the indexing lists of Clarivate, Scopus or the US National Library of Medicine.
Alternatives and next steps if it is not the right fit
| Situation | Route stated by the publisher |
|---|---|
| Manuscript is rejected but may suit another title | The Manuscript Transfer Desk offers a choice of alternative Springer Nature journals; no reformatting is needed and files can transfer automatically, but you must agree to the transfer |
| You do not want a transfer | Decline through the link in the decision letter, or take no action, and the file stays closed |
| Your work is about another neurodegenerative disease | The scope covers translational work on other neurodegenerative diseases; check the aims and scope text against your manuscript |
For background on the field this journal serves, see the CASRAI guides on the Alzheimer’s Disease Neuroimaging Initiative (ADNI), induced pluripotent stem cells, what neurology is and gerontology.
Frequently asked questions
What does Alzheimer’s Research & Therapy publish?
Open access basic research with a translational focus, clinical trials, drug discovery and development research and epidemiologic studies, plus reviews, viewpoints, commentaries, debates and reports (aims and scope, checked 2026-11-08).
How much does it cost to publish?
The APC shown on 2026-11-08 is GBP 3,090, USD 4,390 or EUR 3,490, plus any applicable taxes, charged on acceptance.
Can I get an APC waiver?
The journal offers waivers or discounts for corresponding authors in the lowest-income countries and considers other requests case by case; requests are made at submission.
Which licence applies to published articles?
Authors can choose CC BY-NC-ND 4.0 or CC BY 4.0, and they retain copyright.
Where did the BioMed Central site go?
The journal’s pages are now on Springer Nature Link at link.springer.com/journal/13195.
Sources
- Alzheimer’s Research & Therapy, Aims and scope, read 2026-11-08.
- Alzheimer’s Research & Therapy, journal home page, read 2026-11-08.
- Alzheimer’s Research & Therapy, Submission guidelines, read 2026-11-08.
